[go: up one dir, main page]

AR096322A1 - Derivados de pirimidin-4-il)oxi)-1h-indol-1-carboxamida y uso de los mismos - Google Patents

Derivados de pirimidin-4-il)oxi)-1h-indol-1-carboxamida y uso de los mismos

Info

Publication number
AR096322A1
AR096322A1 ARP140101963A ARP140101963A AR096322A1 AR 096322 A1 AR096322 A1 AR 096322A1 AR P140101963 A ARP140101963 A AR P140101963A AR P140101963 A ARP140101963 A AR P140101963A AR 096322 A1 AR096322 A1 AR 096322A1
Authority
AR
Argentina
Prior art keywords
carboxamide
pirimidin
oxi
indol
derivatives
Prior art date
Application number
ARP140101963A
Other languages
English (en)
Inventor
Glaenzel Ulrike
Nufer Robert
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR096322A1 publication Critical patent/AR096322A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente se refiere a metabolitos de la N-(1-metil-5-(trifluorometil)-1H-pirazol-3-il)-5-((6-((metilamino)metil)pirimidin-4-il)oxi)-1H-indol-1-carboxamida; en particular, la presente se refiere a composiciones farmacéuticas que comprenden estos metabolitos, así como a los procesos para su preparación, y a su uso en el tratamiento de enfermedades. Reivindicación 1: Un metabolito, o una sal del mismo, de la N-(1-metil-5-(trifluorometil)-1H-pirazol-3-il)-5-((6-((metilamino)metil)pirimidin-4-il)oxi-1H-indol-1-carboxamida, que se selecciona entre: el compuesto de fórmula (1), (2) ó (3).
ARP140101963A 2013-05-17 2014-05-16 Derivados de pirimidin-4-il)oxi)-1h-indol-1-carboxamida y uso de los mismos AR096322A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361824464P 2013-05-17 2013-05-17

Publications (1)

Publication Number Publication Date
AR096322A1 true AR096322A1 (es) 2015-12-23

Family

ID=50896374

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140101963A AR096322A1 (es) 2013-05-17 2014-05-16 Derivados de pirimidin-4-il)oxi)-1h-indol-1-carboxamida y uso de los mismos

Country Status (13)

Country Link
US (2) US20150018376A1 (es)
EP (1) EP2997022B1 (es)
JP (1) JP2016518443A (es)
KR (1) KR20160010522A (es)
CN (1) CN105452241B (es)
AR (1) AR096322A1 (es)
AU (1) AU2014266867B2 (es)
BR (1) BR112015028551A2 (es)
CA (1) CA2912130A1 (es)
EA (1) EA201592190A1 (es)
ES (1) ES2699776T3 (es)
MX (1) MX2015015845A (es)
WO (1) WO2014184778A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101973074B1 (ko) * 2018-11-30 2019-04-26 주식회사 티움바이오 퓨로피리미딘 화합물의 염 및 결정형, 및 이를 포함하는 약학적 조성물

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
ATE28864T1 (de) 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
TW225528B (es) 1992-04-03 1994-06-21 Ciba Geigy Ag
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
EP2295415A1 (en) 1995-03-30 2011-03-16 OSI Pharmaceuticals, Inc. Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
CZ1598A3 (cs) 1995-07-06 1998-04-15 Novartis Ag Pyrrolopyrimidiny a způsoby jejich přípravy
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GEP20012442B (en) 1996-04-12 2001-05-25 Warner Lambert Co Irreversible Inhibitors of Tyrosine Kinases
CA2258548C (en) 1996-06-24 2005-07-26 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
AU716610B2 (en) 1996-08-30 2000-03-02 Novartis Ag Method for producing epothilones, and intermediate products obtained during the production process
DE69724269T2 (de) 1996-09-06 2004-06-09 Obducat Ab Verfahren für das anisotrope ätzen von strukturen in leitende materialien
CA2265630A1 (en) 1996-09-13 1998-03-19 Gerald Mcmahon Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
CN1196698C (zh) 1996-11-18 2005-04-13 生物技术研究有限公司(Gbf) Epothilone D、E和F,其制备方法,以及作为细胞抑制剂和植物保护剂的应用
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
EP1058679B1 (en) 1998-02-25 2005-10-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues therof
BR9912938B1 (pt) 1998-08-11 2011-06-28 derivados de isoquinolina, composição que os compreende, processo para preparação e uso dos mesmos.
WO2000031247A2 (en) 1998-11-20 2000-06-02 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
KR100371449B1 (ko) 1999-07-20 2003-02-07 주식회사 아이디어파크 무선 이어폰/마이크를 갖는 착탈형 무선전환장치
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
JO3265B1 (ar) * 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض

Also Published As

Publication number Publication date
US9604969B2 (en) 2017-03-28
AU2014266867A1 (en) 2015-12-03
US20150018376A1 (en) 2015-01-15
WO2014184778A1 (en) 2014-11-20
CA2912130A1 (en) 2014-11-20
AU2014266867B2 (en) 2017-07-13
BR112015028551A2 (pt) 2017-07-25
CN105452241B (zh) 2018-01-05
EA201592190A1 (ru) 2016-04-29
CN105452241A (zh) 2016-03-30
EP2997022B1 (en) 2018-08-29
ES2699776T3 (es) 2019-02-12
EP2997022A1 (en) 2016-03-23
JP2016518443A (ja) 2016-06-23
MX2015015845A (es) 2016-06-29
US20160115156A1 (en) 2016-04-28
KR20160010522A (ko) 2016-01-27

Similar Documents

Publication Publication Date Title
CY1124726T1 (el) Παραγωγα κιναζολινης που χρησιμοποιουνται για την αντιμετωπιση του hiv
SV2016005229A (es) Inhibidores de syk
CL2019001714A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer.
DOP2015000274A (es) Compuestos químicos
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
UY36112A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
MX2018001721A (es) 5-bromo-2,6-di-(1h-pirazol-1-il) pirimidin-4-amina-para su uso en el tratamiento del cancer.
DOP2014000133A (es) Triazolopiridinas sustituidas
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
SV2016005257A (es) Benzimidazol-2-aminas como inhibidores de midh1
CO6690816A2 (es) Derivados de quinazolin-4(3h)-ona utilizados como inhibidores de pi3 cinasa
GT201300254A (es) Triazolopiridinas
DOP2015000170A (es) Compuestos químicos
AR128459A2 (es) Composición farmacéutica sólida comprimida por rodillo y el proceso para su fabricación
CL2017000682A1 (es) Compuestos novedosos de imidazopiridazina y su uso.
CR20160016A (es) Pirazolpiridinas sustituidas
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
MX2016004841A (es) Compuestos de pirimidina substituidos y su uso como inhibidores de la tirosina cinasa del bazo (syk).
CL2017000223A1 (es) [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas
CL2019001004A1 (es) Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismos.
NI201500176A (es) Derivados de prodroga de triazolpiridinas sustituidas
AR096322A1 (es) Derivados de pirimidin-4-il)oxi)-1h-indol-1-carboxamida y uso de los mismos
AR095353A1 (es) Compuesto

Legal Events

Date Code Title Description
FB Suspension of granting procedure